Evidence map›Paper›PMID 40143253›Full record

ArticleViruses2025

Influence of Distinct Maternal Cytomegalovirus-Specific Neutralizing and Fc Receptor-Binding Responses on Congenital Cytomegalovirus Transmission in HIV-Exposed Neonates.

Itzayana G Miller, Aakash Mahant Mahant, Jennifer A Jenks, Eleanor C Semmes, Eric Rochat, Savannah L Herbek, Caroline Andy, Nicole S Rodgers, Justin Pollara, Linda M Gerber and 2 more

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Itzayana G MillerDepartment of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0001-9199-8985
Aakash Mahant MahantDepartment of Microbiology-Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.ORCID 0000-0002-0530-122X
Jennifer A JenksHuman Vaccine Institute, Duke University, Durham, NC 27710, USA.
Eleanor C SemmesHuman Vaccine Institute, Duke University, Durham, NC 27710, USA.
Eric RochatHuman Vaccine Institute, Duke University, Durham, NC 27710, USA.
Savannah L HerbekDepartment of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA.
Caroline AndyDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY 10065, USA.
Nicole S RodgersDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Justin PollaraHuman Vaccine Institute, Duke University, Durham, NC 27710, USA.
Linda M GerberDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0003-0081-3338
Betsy C HeroldDepartment of Microbiology-Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.ORCID 0000-0001-9974-0786
Sallie R PermarDepartment of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA.

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HARRIS GOLDSTEIN · 2017 to 2026
$28.3M
Identifying and modeling immune correlates of protection against congenital CMV transmission after primary maternal infectionR01AI173333 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Sallie R. Permar · 2023 to 2026
$3.3M
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV DiseaseR01AI177673 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Betsy C. Herold, Masayuki Kuraoka · 2023 to 2026
$2.4M
Weill Cornell Initiative for Maximizing Student DevelopmentR25GM130494 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI CARRASCO, YAZMIN PAULINA, CESARMAN, ETHEL · 2019 to 2023
$2.4M
Humoral Immune Correlates of Protection against Congenital CMV and HSV Transmission in HIV-Infected WomenR21AI147992 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI HUGHES, BRENNA L., PERMAR, SALLIE R. · 2019 to 2020
$478k
Immune correlates of protection against nonprimary congenital cytomegalovirus transmission in an HIV-infected mother-infant cohortF30HD100170 · NICHD · DUKE UNIVERSITY · PI JENKS, JENNIFER · 2020 to 2022
$61k
NIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI173333NIAID NIH HHS R01 AI177673NIAID NIH HHS R21 AI147992NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI106716NICHD NIH HHS F30 HD100170NICHD NIH HHS HHSN275201800001CNICHD NIH HHS HHSN275201800001INIGMS NIH HHS R25 GM130494NIH HHS 1R01AI173333-24A1NIH HHS 1R01AI177673-24A1NIH HHS 1R21AI147992-20A1
6 · The paper itself

Abstract

Congenital cytomegalovirus (cCMV) is the most common infectious cause of birth defects worldwide, affecting approximately 1 in every 200 live-born infants globally. Recent work has identified potential immune correlates of protection against cCMV transmission including maternal and placentally transferred antibody levels and their function, which may inform the development of maternal active (vaccine) and passive (mono/polyclonal antibody) immunizations. However, these correlates need to also be assessed in diverse cohorts, including women living with HIV who have increased risk of cCMV transmission. Using a case-control design, we investigated whether the magnitude, specificity, function and placental transfer of maternal IgG responses are associated with protection against and/or risk of cCMV transmission in HIV/HCMV co-infection. Within 3 historical cohorts of pregnant women with HIV/HCMV co-infection, we identified 16 cCMV transmitting cases that were matched to 29 cCMV non-transmitting controls. Using a systems serology approach, we found that normalized HCMV-specific IgG binding to FcγR1α was higher in non-transmitting dyads, whereas HCMV-neutralizing antibody responses were higher in transmitting dyads. These findings suggest that engagement of FcγR1α by HCMV-specific IgG may help confer protection against cCMV transmission. Building upon previous research, our study reinforces the critical role of validating maternal humoral immune correlates of cCMV transmission risk across diverse seropositive cohorts, providing essential insights to inform and accelerate the development of effective HCMV vaccines.

Indexed as

Antibodies, NeutralizingCytomegalovirusCytomegalovirus InfectionsHIV InfectionsInfectious Disease Transmission, VerticalPregnancy Complications, InfectiousReceptors, FcAdultAntibodies, ViralCase-Control StudiesCoinfectionFemaleHumansImmunoglobulin GInfant, NewbornPregnancyAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GReceptors, FccytomegalovirusHCMVhumoral immunity

Identifiers

PMID40143253
PMCPMC11946089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.